MOHW-Roche have difficulty discussing resupply of Madopar
By Lee, Jeong-Hwan | translator Kim, Jung-Ju
23.08.26 05:50:39
°¡³ª´Ù¶ó
0
Roche expresses its position on how it cannot resupply the drug in Korea due to the facility cost required to manufacture Korea¡¯s supply
The government proposes measures, such as informing Roche about drug price increase procedures
Roche Korea is known to have refused to supply Madopar Tab to Korea, citing how additional administrative procedures are required to resupply Madopar and that significant expenses are required to produce quantities for export to Korea.
On the 25th, the MOHW responded, "We will find a way to solve the patient's difficulties, including resupply," to a written inquiry submitted by Rep Eun-mi Kang, a member of the Justice Party and
Lee, Jeong-Hwan(junghwanss@dailypharm.com)
If you want to see the full article, please JOIN US (click)